Acquisitions (Tables)

12 Months Ended

Dec. 31, 2012

Thomas Medical Products, Inc [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The total purchase price was preliminarily allocated as follows (in thousands):

Assets Acquired
Trade receivables	$	6,507
Inventories	5,459
Prepaid expenses	340
Property and equipment	2,685
Intangibles
Developed technology	43,000
Non-compete agreements	500
Customer lists	5,000
Trademarks	1,400
Goodwill	102,407
Total assets acquired	167,298
Liabilities Assumed
Trade payables	588
Accrued expenses	1,094
Total liabilities assumed	1,682
Net assets acquired, net of cash acquired of $1,829	$	165,616

Business Acquisition, Pro Forma Information [Table Text Block]

The following table summarizes our unaudited consolidated results of operations for the years ended December 31, 2012 and 2011, as well as unaudited pro forma consolidated results of operations as though the Thomas Medical, MediGroup and Ostial acquisitions had occurred on January 1, 2011 (in thousands, except per common share amounts):

	2012				2011
	As Reported		Pro Forma		As Reported		Pro Forma
Net sales	$	394,288	$	431,861	$	359,449	$	396,767
Net income	19,710		24,296		23,044		22,033
Earnings per common share:
Basic	$	0.47	$	0.58	$	0.59	$	0.56
Diluted	$	0.46	$	0.57	$	0.58	$	0.55

MediGroup [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The total purchase price, which includes the contingent consideration liability described above, was preliminarily allocated as follows (in thousands):

Assets Acquired
Inventories	$	263
Property and equipment	79
Intangibles
Developed technology	2,000
Non-compete agreements	210
Customer lists	110
Trademarks	80
Goodwill	1,697
Total assets acquired	$	4,439

Ostial Solutions, LLC [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

It is not practical to separately report the earnings related to the Ostial acquisition, as we cannot split out sales costs related to Ostial products, principally because our sales representatives are selling multiple products (including Ostial products) in the cardiovascular business segment. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):

Assets Acquired
Intangibles
Developed technology	$	10,500
Customer lists	600
Trademark	110
Non-compete agreements	10
Goodwill	9,580
Total assets acquired	$	20,800

Ash [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):

Assets Acquired
Property and equipment	$	73
Intangibles
Developed technology	3,200
Customer lists	300
Goodwill	2,697
Total assets acquired	$	6,270

BioSphere [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

As of December 31, 2010, the BioSphere purchase price was allocated as follows (in thousands):

Assets Acquired
Marketable securities	$	9,673
Trade receivables	4,529
Inventories	5,694
Other assets	1,340
Property and equipment	546
Deferred income tax assets	16,012
Intangibles
Developed technology	19,000
Customer list	7,900
License agreement	380
Trademark	3,200
Goodwill	34,016
Total assets acquired	102,290
Liabilities Assumed
Accounts payable	322
Accrued expenses	3,617
Deferred income tax liabilities	729
Liabilities related to unrecognized tax benefits	961
Other liabilities	936
Total liabilities assumed	6,565
Net assets acquired, net of cash acquired of $274	$	95,725

Business Acquisition, Pro Forma Information [Table Text Block]

The following table summarizes our consolidated results of operations for the year ended December 31, 2010, as well as the pro forma consolidated results of operations as though the BioSphere acquisition had occurred on January 1, 2010 (in thousands, except per share amounts):

	Year Ended December 31, 2010
	As Reported		Pro Forma
Sales	$	296,755	$	317,382
Net income	12,460		7,258
Earnings per common share:
Basic	$	0.35	$	0.21
Diluted	$	0.35	$	0.20